NCT06900218 2025-04-02
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
Clinical Trials
3 trialsNCT06680115 2024-11-08
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
First Affiliated Hospital of Guangxi Medical University
Phase 2 Not yet recruiting
NCT06364826 2024-04-15
Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting